MacroGenics faces new competition
Duality takes its Adam9-targeting conjugate into the clinic.
Colorectal cancer is next for VEGF bispecifics
Pumitamig is the latest to be tested in first-line disease.
The month ahead: September’s upcoming events
It’s a new term for biotech and its investors.
Ivonescimab back in tune
China's Harmoni-A trial hits on overall survival, but hopes for a global phase 3 seem optimistic.
A new multiple myeloma race heats up
Qilu moves its GPRC5D T-cell engager into phase 3, but trispecifics set the new pace.
FDA doubles down on overall survival
New draft guidance could see the agency getting ever stricter.
